论文部分内容阅读
Purpose:The objective of our study was to determine the QTc effects of iptakalim hydrochloride(ITKL).Methods:A crossover-design thorough QT study of recommended(10 mg once daily,4 days)and supra-therapeutic(20 mg once daily,4 days)doses of ITKL,moxifloxacin(400 mg once daily,4 days),and placebo was performed.Electrocardiograms(ECGs)and pharmacokinetic samples were obtained on days 1-4; time-matched baseline ECGs were taken on day 0.The primary end point was the mean placebo-subtracted change from baseline Fridericia-corrected QT(QTcF)during peak drug exposure on day 4.Findings:Mean QTcF prolongation of moxifloxacin was 12.84 ms(machine-read)and 14.21 ms(manual-read).At recommended and supra-therapeutic iptakalim doses,mean QTcF prolongation was 2.55 and 1.55 ms(machine-read),respectively,and4.17 and 7.16(manual-read),respectively.The QTc effect of iptakalim was lower than that of moxifloxacin.No subject receiving iptakalim exceeded the clinically relevant thresholds of 500 ms absolute QTc or 60 ms change from baseline.Implications:In conclusion,iptakalim does not have a clinically significant effect on QT interval.